Skip to Content

Xeris Biopharma Holdings Inc XERS

Morningstar Rating
$2.21 +0.17 (8.33%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

XERS is trading at a 28% discount.
Price
$2.12
Fair Value
$7.99
Uncertainty
Very High
1-Star Price
$4.29
5-Star Price
$9.86
Economic Moat
Dlhf
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if XERS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.04
Day Range
$2.112.28
52-Week Range
$1.313.26
Bid/Ask
$2.18 / $2.22
Market Cap
$310.40 Mil
Volume/Avg
3.2 Mil / 2.3 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
1.86
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield
0.33%

Company Profile

Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
377

Comparables

Valuation

Metric
XERS
ICVX
EWTX
Price/Earnings (Normalized)
Price/Book Value
3.304.03
Price/Sales
1.86
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
XERS
ICVX
EWTX
Quick Ratio
1.1717.5918.98
Current Ratio
1.6418.0619.50
Interest Coverage
−1.57
Quick Ratio
XERS
ICVX
EWTX

Profitability

Metric
XERS
ICVX
EWTX
Return on Assets (Normalized)
−16.34%−29.30%−24.36%
Return on Equity (Normalized)
−312.66%−31.87%−25.87%
Return on Invested Capital (Normalized)
−13.88%−34.69%−29.82%
Return on Assets
XERS
ICVX
EWTX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRVdlzwbnjxWxvy$570.1 Bil
VRTX
Vertex Pharmaceuticals IncHrgfgfwbwVkqhk$108.0 Bil
REGN
Regeneron Pharmaceuticals IncSsmlbvsjLxhnxj$105.6 Bil
MRNA
Moderna IncRbbhqlxcGvvt$40.8 Bil
ARGX
argenx SE ADRPqflxpfBqlyr$23.5 Bil
BNTX
BioNTech SE ADRLrjrkrfsfZyff$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncZmngcqpmzVnwdyf$18.8 Bil
BMRN
Biomarin Pharmaceutical IncSdtqlnylTqrvsm$16.5 Bil
RPRX
Royalty Pharma PLC Class AJbrhmjspSqhfpvc$13.6 Bil
INCY
Incyte CorpTwnkyxgvzQccvzv$12.8 Bil

Sponsor Center